Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q1 2024 · 10-Q
Revenue—
Net Income-$6.83M-$6.83MN/M vs Q1 2023 EPS Diluted-$368.21-$368.21N/M vs Q1 2023 Operating Income-$6,983,000N/M Operating Cash Flow-$6,651,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end